Fate Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical firm focused on cellular immunotherapies for cancer, will present at several upcoming investor conferences. Notable events include the Jefferies London Healthcare Conference on November 18, 2021, the Piper Sandler 33rd Annual Healthcare Conference on November 23, 2021, and the Evercore ISI HealthCONx Conference on November 30, 2021. These presentations will be available on demand, and a live webcast will be accessible via the company's website. Fate Therapeutics aims to enhance cancer treatments with innovative cell therapies.

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

• Jefferies London Healthcare Conference available on demand on Thursday, November 18^th, 2021 at 8:00 AM GMT, 3:00 AM ET
• Piper Sandler 33^rd Annual Healthcare Conference available on demand on Tuesday, November 23^rd, 2021 at 10:00 AM ET
• Evercore ISI 4^th Annual HealthCONx Conference on Tuesday, November 30^th, 2021 at 9:40 AM ET
  

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

When will Fate Therapeutics present at the Jefferies London Healthcare Conference?

Fate Therapeutics will present at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 AM GMT.

What is the date for the Piper Sandler Healthcare Conference presentation by Fate Therapeutics?

The Piper Sandler 33rd Annual Healthcare Conference presentation is scheduled for November 23, 2021, at 10:00 AM ET.

Which conference will Fate Therapeutics attend on November 30, 2021?

Fate Therapeutics will attend the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 9:40 AM ET.

Where can I watch the presentations from Fate Therapeutics' upcoming conferences?

Presentations will be available on demand, and webcasts can be accessed under 'Events & Presentations' on Fate Therapeutics' website.

What is Fate Therapeutics' focus in the biopharmaceutical field?

Fate Therapeutics focuses on developing cellular immunotherapies for cancer, utilizing induced pluripotent stem cell technology.